As the drug discovery industry takes on the complex disease states that plague our world, the need for more relevant and timely answers from cell-based assays has become a major challenge.
List view / Grid view
24 January 2018 | By Drug Target Review
Scientists have successfully blocked the powerful call of two types of aggressive cancer – glioblastoma and breast cancer – in laboratory models; with evidence that inhibiting the chemical 20-HETE halts tumour growth.
Application note: High throughput quantitation of cytokine biomarkers using LANCE Ultra TR-FRET assays
In this application note, PerkinElmer demonstrates the sensitivity, robust performance, and HTS suitability of the LANCE Ultra cytokine biomarker kits.
26 September 2017 | By IntelliCyt Corporation
This application note illustrates the value of multiplexing, rapid sampling, and assay miniaturisation using QBeads on the iQue Screener...
22 September 2017 | By IntelliCyt Corporation
In this webinar, Belen Ybarrondo, Ph.D and Thomas Duensing, Ph.D discuss the need for robust high content tools for current immunotherapeutic approaches, and how IntelliCyt's iQue Screener PLUS can give functional efficacy of immuno-oncology therapies...
19 September 2017 | By Dr Zara Kassam (Drug Target Review)
Scientists have uncovered two closely related cytokines molecules involved in cell communication that explain why some people develop progressive MS...
Application note: Application of MultiCyt QBeads for high throughput cytokine profiling in human peripheral blood mononuclear cells
In this application note IntelliCyt Corporation report on the development and validation of their family of MultiCyt QBeads for the detection of cytokines in a high-throughput screening application on the iQue Screener...
3 October 2016 | By Niamh Louise Marriott, Digital Content Producer
Researchers found that A549-DR was resistant to the chemotherapeutic drug when transplanted in mice, while A549-DR with depleted IL-34 became sensitive...